Pfizer and BMS Score Approval for Orthopedic Drug

Xconomy New York — 

The European Commission has approved apixaban (Eliquis), developed by Pfizer and Bristol-Myers Squibb, for the prevention of venous thromboembolic events (VTE) in adult patients who have undergone elective hip or knee replacement surgery, according to a press release. The two New York companies have an alliance to develop the drug, which is a new oral direct Factor Xa inhibitor. This is the first approval for apixaban, which is also up for review with the FDA.